Neural Stem Cell Therapy for Ischemic Stroke Patients

The single largest cause of adult disability in the developed world is ischemic stroke, in which blood flow in or to the brain is blocked. It precipitates immense amounts of social and financial costs. Currently, therapies for stroke focus on prevention or acute phase treatments that arrest the stroke while it is happening. But many patients are not fortunate enough to get acute phase treatment and suffer neurological damage that leads to functional and cognitive impairment. Until now, there have been almost no options for such patients. But last February, a company called ReNeuron received approval to begin a clinical trial of neural stem cell therapy for disabled stroke patients [1]. Two patients have been treated thus far and the therapy appears to be safe.

Neural stem cell therapy

Updated Rates of the Most Common Neurological Disorders

An up-to-date review of the most common neurological disorders in the United States was published in the January 30th issue of Neurology [1]. Researchers reviewed nearly 500 articles published between 1990 and 2005 to determine the rates of prevalence (meaning the total number of cases of a disease in a given population at a specific time; does not convey information about risk) or incidence (meaning the rate of occurrence of new cases of a particular disease in a given population; measures the risk of a disease) for 12 neurological disorders.